Clinical trials
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype clinical trials
Below are recruiting glioblastoma idh (isocitrate dehydrogenase) wildtype clinical trials, each written for real people, not researchers. We’re tracking 11 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07520214Enrolling by invitationEarly Phase 1
Cancer vaccine to prevent glioblastoma recurrence
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07416188RecruitingPhase 1/Phase 2
LMP744 drug for returning glioblastoma
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Bethesda, MarylandAges 18–99 - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
Chicago, IllinoisAges 18 years+ - NCT05789394RecruitingPhase 1
Stem cell treatment for recurrent brain tumor surgery
This Phase 1 study tests an “allogenic” stem cell product made from donated fat tissue to treat recurrent glioblastoma or certain recurrent astrocytoma. It gives the treatment around the time of a repeat brain surgery, and focuses on safety while also studying why it might help.
Jacksonville, FloridaAges 18 years+ - NCT05864534RecruitingPhase 2
Ultrasound plus immune treatment after new glioblastoma diagnosis
This trial tests whether using focused ultrasound to help adjust the immune system can improve outcomes for people with newly diagnosed glioblastoma. You’d already complete standard brain radiation (with or without temozolomide), then undergo an ultrasound-based immune modulation approach.
Chicago, IllinoisAges 18 years+ - NCT05879250RecruitingPhase 2
WP1066 plus radiation for newly diagnosed glioblastoma
This trial tests whether the study drug WP1066 combined with radiation can better control newly diagnosed glioblastoma, a fast-growing brain tumor. It also aims to check safety and how well tumors respond by using brain scans.
Chicago, IllinoisAges 18 years+ - NCT05879367RecruitingPhase 1
Eflornithine plus temozolomide for newly diagnosed brain cancer
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
Birmingham, AlabamaAges 18 years+ - NCT06410248RecruitingPhase 1
Triapine and temozolomide for recurrent glioblastoma
This trial tests a combination of two drugs, triapine and temozolomide, for people whose glioblastoma has come back after initial treatment. The goal is to see if this combination can help control the tumor.
Chicago, IllinoisAges 18 years+ - NCT06430424Recruiting
Study of body markers in recurrent glioblastoma
This study looks at special markers in the blood and tumors of people whose glioblastoma has come back. It may help doctors understand why the cancer returns and how to treat it better.
BordeauxAges 18 years+ - NCT07111195Recruiting
Using ONCOhabitats to plan brain tumor surgery
This study tests a computer tool called ONCOhabitats that helps doctors plan surgery and treatment for a type of aggressive brain tumor called glioblastoma. By using your MRI scans, the tool may help guide the surgeon to remove as much tumor as possible while sparing healthy brain tissue.
AlicanteAges 18 years+ - NCT07668869Recruiting
Electric fields with targeted radiation vs. alone for recurrent brain cancer
This trial tests whether adding a precise, MRI-guided radiation treatment to tumor-treating electric fields (TTFields) can help people with recurrent glioblastoma. You may qualify if your tumor has come back 1 to 3 times after standard therapy and you haven't had certain prior treatments.
BydgoszczAges 18 years+
Hear when a new Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for glioblastoma idh (isocitrate dehydrogenase) wildtype?
- Yes. Clin2 currently lists 11 recruiting glioblastoma idh (isocitrate dehydrogenase) wildtype studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glioblastoma idh (isocitrate dehydrogenase) wildtype trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glioblastoma idh (isocitrate dehydrogenase) wildtype trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.